<DOC>
	<DOC>NCT01528345</DOC>
	<brief_summary>This trial is designed to enroll postmenopausal patients with locally advanced or metastatic, HER2- and HR+ breast cancer not amenable to curative treatment by surgery or radiotherapy, and whose disease has progressed on or after prior endocrine therapy. Patients must undergo molecular pre-screening prior to entry.</brief_summary>
	<brief_title>Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal women with HER2, HR+ locally advanced or metastatic breast cancer Progression on or after endocrine treatment Measureable disease as per RECIST ECOG 0, 1 or 2 Evidence of CNS or leptomeningeal metastases Previous treatment with fulvestrant Previous chemotherapy for locally advanced or metastatic breast cancer Cirrhosis or chronic active/persistent hepatitis Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2-, HR+</keyword>
	<keyword>post-menopausal</keyword>
	<keyword>Locally advanced or metastatic Breast Cancer (HER2-, HR+)</keyword>
</DOC>